19 December 2016
NHS England has announced £6.9 million of new funding to support and spread the work of the national Cancer Vanguard.
The Cancer Vanguard is a partnership between the UCLH Cancer Collaborative (which includes London Cancer and covers north central and north east London, and west Essex),
Greater Manchester Cancer Vanguard Innovation and RM Partners (north west and south west London). Together we serve a population of over 10 million and we are working to change the way cancer care is provided. Vanguards are tasked with developing models of care that can be replicated across the NHS to improve patient outcomes and experience.
The UCLH Cancer Collaborative (including London Cancer) is currently focusing on a number of programmes, including earlier diagnosis of bowel and lung cancer, changing the way chemotherapy is provided and working with partners across our sector to improve cancer patient pathways of care.
Prof Geoff Bellingan, Medical Director, Surgery and Cancer, said:
“As a national Cancer Vanguard we are transforming earlier cancer diagnosis and trialling new care models for cancer patients, including through a series of partnerships with pharma companies to make better use of cancer drugs. We are also developing options for long term health system improvement, such as the prime provider model. We are working together to ensure that people can live well after a cancer diagnosis, as well as receiving high quality palliative and end of life care where appropriate.”
Roger Spencer, Chair of the Cancer Vanguard Board and Chief Executive of The Christie, said:
“Today’s announcement is hugely positive and a very tangible demonstration that the NHS leadership is prepared to invest in improving cancer patient outcomes and experience.
“Over the next year the support from the national vanguard programme will enable us to conclude our important programme of work, crystallising models that can be replicated and adopted throughout the NHS. The emergence of the new national Cancer Alliances presents an outstanding opportunity to cascade these models and achieve long term impact for patient benefit.”
Nicola Hunt, managing director, RM Partners, said: “We are delighted to have received this funding from NHS England. It will enable us to continue to improve the care of everyone affected by cancer and achieve world-class cancer outcomes for our population across London and Manchester.”
Samantha Jones, Director of the New Care Models Programme said: “The vanguards are making great progress and have already made a tangible impact on the lives of patients and the working lives of staff. 2017/18 is a crucial year for the vanguards, in particular how we further spread their work across the wider NHS and care services. This funding, as well as the support we offer to them, will help them to continue to move at pace.”
Nationally, the total funding allocated to the national Cancer Vanguard is the same as 2016/17 levels and will be matched by funds and resources from the vanguards themselves. New models of care, including the work of the vanguards, are key to the delivery of sustainability and transformation plans (STPs) which are being developed across the country.
To secure funding, vanguards will need to meet a number of robust conditions – local evaluation remains a critical part of the programme and will be funded separately.